--- a
+++ b/clusters/3009knumclusters/clust_31.txt
@@ -0,0 +1,806 @@
+Currently breast feeding.
+The subject is pregnant or breast feeding
+Women who are pregnant or breast-feeding
+Pregnant or breast feeding women are excluded from this study
+Pregnant or breast-feeding women may not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal
+Pregnancy or breast-feeding
+Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal
+Women must not be pregnant or breast-feeding
+Women must not be pregnant or breast-feeding
+Pregnant or breast feeding women
+Pregnant or breast-feeding
+Patients who are pregnant or breast-feeding
+Pregnant, planning a pregnancy or breast feeding during the study
+Patients found to be pregnant/breast feeding
+Female patients who are pregnant or breast-feeding
+ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Women must not be pregnant or breast-feeding
+ELIGIBILITY CRITERIA - PHASE II (ARM D): Women must not be pregnant or breast-feeding
+Patients who are breast feeding
+Pregnant or breast-feeding women
+Pregnant or breast-feeding women
+Pregnant or breast-feeding females
+Pregnant or breast-feeding women, or intending to become pregnant during the study
+Pregnant or breast feeding or plans to become pregnant within 6 months of AVB-620 administration.
+Not breast feeding at any time during the study.
+Pregnant or breast-feeding women.
+Not currently pregnant or breast feeding
+Women who are pregnant or breast feeding
+Woman of childbearing potential that is pregnant or breast-feeding, or planning to become pregnant or breast-feed during protocol treatment and for 3 months after last dose of talimogene laherparepvec
+Not breast feeding at any time during the study.
+Pregnant or breast feeding females.
+Pregnancy or breast-feeding
+Women who are pregnant or are breast feeding.
+Women who are pregnant or breast-feeding
+Pregnant or breast feeding females.
+Not breast feeding at any time during the study.
+Pregnancy or breast-feeding
+Breast feeding or pregnant
+Pregnant, planning a pregnancy, or breast feeding
+Women must not be breast-feeding
+Pregnant women or women who are breast-feeding
+Patients who are pregnant or breast-feeding will NOT be eligible for participation
+Female patients who are lactating must agree to stop breast-feeding
+Patients who are pregnant or breast-feeding
+Pregnant or breast feeding.
+The participant is pregnant or breast-feeding
+The subject is pregnant or breast-feeding
+Pregnant or breast feeding
+Pregnant or breast feeding females.
+Current pregnancy or breast feeding; pregnant women are excluded from this study; breastfeeding should be\r\ndiscontinued in all female subjects
+Women who are pregnant or breast feeding.
+Pregnancy or breast feeding.
+Women who are pregnant or breast-feeding
+Pregnant or breast-feeding women.
+The participant is pregnant or breast-feeding
+Pregnancy or breast-feeding.
+Females who are pregnant or breast feeding are excluded since there are unknown teratogenic effects of these agents
+Participant is breast feeding or pregnant.
+Women who are breast feeding.
+Pregnant or breast feeding females (lactating females must agree not to breast feed while taking the study drugs)
+Female patients who are pregnant (per institutional practice) or breast-feeding.
+A woman who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or within 5 months after the last dose of study drug
+Pregnant or breast-feeding women
+Pregnancy or breast feeding.
+Not pregnant or breast feeding
+Not breast feeding at any time during the study.
+Women who are pregnant or breast-feeding.
+Breast feeding
+The patient is pregnant or breast feeding.
+Women who are pregnant or breast-feeding
+Pregnant or nursing women are excluded from this study, breast feeding should be discontinued
+Subject is pregnant or breast-feeding.
+Women who are pregnant or breast-feeding
+Female patients who are pregnant or are breast feeding.
+Subject who is pregnant (as confirmed by pregnancy test), planning on becoming pregnant during the follow-up period, or actively breast-feeding; and
+Pregnant or breast-feeding women
+Pregnant or breast-feeding females
+Female subject is pregnant or breast-feeding; lactating females must agree not to breastfeed while taking lenalidomide
+Women who are pregnant or breast feeding.
+Pregnant or breast feeding
+Patients who are pregnant or breast-feeding
+Pregnancy or active breast feeding
+Pregnant or breast-feeding.
+Women who are pregnant or currently breast feeding
+Pregnant or breast feeding females
+Pregnant or breast-feeding women
+Females of child-bearing potential cannot be pregnant or breast-feeding; female participants >= 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment; female participants who are breast feeding must agree to stop breast feeding
+Pregnant or breast-feeding women
+Pregnant and breast-feeding patients are not eligible for the study
+Pregnant or breast-feeding
+Women may not be pregnant or breast-feeding
+Pregnant or breast-feeding females are excluded
+Females who are pregnant or breast-feeding
+Women who are pregnant or breast-feeding.
+Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide).
+Pregnant or breast feeding.
+Pregnancy or breast feeding.
+Pregnancy and breast feeding.
+Pregnant or breast-feeding women
+Women who are nursing must discontinue breast-feeding prior to the enrollment in the trial
+Pregnant or breast-feeding females
+Women must not be pregnant or breast-feeding
+Pregnancy or breast-feeding women
+A female patient who is pregnant or breast-feeding
+Women who are pregnant or breast-feeding at enrollment
+Pregnancy or breast feeding.
+Breast feeding or pregnant.
+Patients must not be women who are pregnant or breast feeding.
+Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Women of childbearing age must obtain a pregnancy test and pregnant or breast feeding females are excluded
+Pregnant or breast-feeding women
+Women who are pregnant or breast feeding
+Pregnant or breast feeding
+Pregnant or breast feeding
+Pregnancy or mothers who are breast feeding.
+Pregnant or breast-feeding woman will not be entered on this study
+Pregnant, breast feeding, or planning to become pregnant
+Women who are pregnant or breast feeding
+The patient is pregnant or breast-feeding
+Women who are pregnant or breast-feeding
+Pregnancy or breast-feeding within 30 days prior to enrollment
+Pregnancy and breast feeding
+Pregnant or breast feeding females
+Pregnant or breast feeding
+Pregnant or breast-feeding females
+Female subjects who are pregnant or breast-feeding
+Pregnant or breast-feeding
+Subject is pregnant, breast-feeding or lactating.
+Pregnant or breast-feeding females
+Females who are pregnant or breast-feeding
+Patient is pregnant or breast-feeding
+Pregnant or breast-feeding females.
+Pregnant or breast-feeding females.
+Women who are pregnant or breast-feeding
+Pregnancy or breast-feeding
+Women who are pregnant or breast-feeding
+Patients who are pregnant or breast feeding
+Pregnancy or breast-feeding
+Breast feeding after pregnant
+Patient is pregnant or breast feeding.
+Pregnant or currently breast-feeding
+Pregnant or breast feeding
+Pregnant or breast feeding
+Breast-feeding at screening or planning to become pregnant during the course of therapy
+Pregnant or breast feeding
+Women who are pregnant or breast-feeding
+Women who are pregnant or breast-feeding
+Currently pregnant or breast-feeding
+Pregnancy or breast-feeding at time of Screening and throughout the study.
+Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
+Pregnant or breast feeding females
+Pregnant or breast-feeding females
+Pregnant and breast-feeding subjects
+Pregnant or breast-feeding
+Patients must not be pregnant/breast feeding and must agree to practice adequate contraception.
+Female patients who are pregnant or breast feeding are not eligible
+Patient is pregnant or breast-feeding
+Women who are pregnant or breast-feeding
+Women who are pregnant or breast-feeding.
+Pregnancy or breast-feeding
+Women who are pregnant or breast-feeding currently or are planning to do so during or up to 3 months after the end of protocol therapy.
+Women who are breast feeding are not eligible
+Women who are pregnant or breast-feeding
+Breast feeding or pregnant
+Pregnant or breast-feeding women
+Pregnant or breast feeding
+Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
+Pregnancy or breast feeding female
+Subject is pregnant or breast feeding, or planning to become pregnant/breastfeed while on study through 5 months after the end of treatment
+Women who are breast-feeding or pregnant as evidenced by positive urine pregnancy test done within 72 hours of first dosing
+Female patients who are pregnant or breast-feeding
+DONOR: Pregnant or breast-feeding
+Women who are breast feeding
+Pregnant women and women who are breast-feeding
+Patient is pregnant or breast-feeding
+Pregnant or breast-feeding women
+Not breast feeding
+DONOR: Not breast feeding
+Pregnant or breast-feeding women are excluded
+Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
+Pregnant or breast-feeding women are NOT eligible; pregnancy tests must be obtained in females who are post-menarchal
+If female, is pregnant or is breast feeding.
+Women who are pregnant or breast-feeding
+Pregnant or breast feeding
+Patient is pregnant or breast-feeding
+Breast feeding or pregnant
+Pregnancy or breast feeding.
+Pregnant or breast feeding females are excluded
+Women who are breast-feeding
+Breast-feeding at screening or planning to become pregnant during the course of therapy
+Women who are pregnant or breast-feeding
+Pregnant or currently breast-feeding
+Pregnant or breast-feeding
+Pregnancy or breast-feeding
+Women who are pregnant or breast-feeding
+Pregnant, lactating or breast feeding woman
+Patient is pregnant or breast-feeding
+Pregnant or breast-feeding women.
+Pregnant or breast feeding
+Pregnancy or breast feeding
+Subjects who are pregnant or breast-feeding
+Patient is breast feeding.
+Women who are pregnant or breast feeding.
+Women who are pregnant or breast-feeding
+The patient is pregnant or breast-feeding
+Pregnant and breast-feeding females
+Pregnancy or breast feeding
+Women who are pregnant or breast-feeding.
+Breast feeding
+Breast-feeding, pregnant, or likely to become pregnant during the study
+Female participants of child-bearing potential cannot be pregnant or breast-feeding
+Pregnant women or women who are breast-feeding
+Women that are currently breast feeding
+Pregnant women or women who are breast-feeding
+Breast feeding women
+Pregnancy or breast feeding
+Pregnant or breast feeding women due potential damage to the fetus
+Pregnant or breast-feeding
+Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment
+Breast feeding women
+Pregnant, lactating or breast feeding women
+Pregnant or breast feeding females
+Patient is pregnant or breast-feeding
+Pregnant or breast-feeding women will not be entered on this study
+Breast feeding and/or pregnant women
+Pregnancy or breast feeding
+Pregnant or breast-feeding
+Women of child-bearing potential who are pregnant or breast feeding
+Pregnant or breast-feeding women will not be entered on this study
+Pregnant and breast feeding women
+Pregnant or breast-feeding women
+Female patients who are lactating must agree to stop breast feeding
+Pregnancy or breast feeding
+Are pregnant or breast-feeding women.
+Pregnant or breast-feeding females are excluded
+Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
+Pregnant or breast feeding females
+TREATMENT: Pregnant or breast feeding
+Pregnancy or breast-feeding
+Women who are pregnant or are breast-feeding
+Subjects who are breast-feeding and plan to continue breast-feeding during therapy, or have a positive pregnancy test will be excluded from the study; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
+Female patients who are lactating must agree to stop breast-feeding
+Pregnant or breast-feeding women
+Pregnant or breast feeding females
+Pregnancy, breast-feeding or planning to become pregnant
+Pregnancy or breast-feeding
+Pregnancy or breast feeding. Due to the potential teratogenic effects of retinoids, pregnant women are NOT eligible. Breast milk feeding by study patient is NOT allowed
+Breast feeding females
+Active breast-feeding is also not allowed on study enrollment
+Patients who are pregnant or breast-feeding
+Pregnancy or unwillingness to stop breast-feeding
+Pregnant or breast-feeding patients
+Females who are pregnant or breast-feeding
+Pregnant or breast-feeding women
+Pregnant or breast-feeding females; (lactating females must agree not to breast-feed while taking lenalidomide)
+The subject is pregnant or breast-feeding
+Relapsed/refractory MCL: Pregnant or breast feeding females
+Pregnant or breast feeding (female of child-bearing potential)
+Not breast feeding
+DONOR: Not breast feeding
+DONOR: Pregnant or breast-feeding
+Pregnant women or women who are breast-feeding
+Pregnant or breast-feeding females; lactating females must agree not to breast-feed while taking lenalidomide
+Patients who are pregnant or breast-feeding.
+Patients who are pregnant or breast-feeding.
+Females who are pregnant or breast-feeding
+If female, subject is pregnant or breast-feeding
+Female patients who are pregnant or breast-feeding
+Pregnant or breast-feeding women
+Pregnant or breast-feeding females
+Breast feeding (if lactating, must agree not to breast feed while taking pomalidomide)
+Patients who are pregnant or breast-feeding
+Women of child-bearing potential who are pregnant or breast feeding
+Known pregnancy or breast feeding
+Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
+Pregnant women or women who are breast-feeding
+Pregnant or breast-feeding patients
+Known pregnancy or breast-feeding
+Pregnant or breast-feeding women are excluded
+Pregnant or breast-feeding patients are excluded from this study
+Not pregnant or breast-feeding
+Female patients who are pregnant or breast-feeding
+Pregnancy or breast-feeding
+Pregnant or breast feeding
+Pregnant or breast-feeding women due to the known birth defects association with the treatments used in this study
+Pregnancy or breast feeding
+Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
+Patient is pregnant or breast-feeding.
+Women who are breast feeding.
+Women who are pregnant or breast feeding
+Pregnancy or breast feeding.
+Pregnancy or breast feeding
+Females who are pregnant or breast-feeding.
+Women who are pregnant or breast feeding
+Pregnancy or breast feeding
+Pregnant or breast-feeding
+Female patients who are pregnant, breast-feeding, or planning to become pregnant
+Pregnant or breast-feeding
+Pregnant or breast-feeding
+Women who are pregnant or breast-feeding;
+Pregnant or breast-feeding.
+Women who are pregnant or breast-feeding
+Pregnant, planning to become pregnant, or breast feeding.
+Breast feeding women.
+Female patients who are breast-feeding.
+Pregnant or breast-feeding women
+Female patients should not be pregnant or breast?feeding
+Women who are pregnant or breast-feeding
+Female patients must not be pregnant or breast-feeding
+Women who are pregnant or breast feeding.
+Be female and pregnant or breast feeding.
+Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
+Pregnant or breast feeding
+Pregnancy or breast-feeding
+Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will be excluded from participation
+Pregnant or breast feeding females.
+Pregnant or breast feeding women are excluded from this study
+Pregnant or breast feeding
+Women who are actively breast feeding
+Pregnant or breast feeding
+Women who are nursing must discontinue breast-feeding prior to the enrollment in the trial
+Pregnancy or breast feeding
+Women who are breast feeding
+Participants cannot be breast feeding
+Pregnancy or breast feeding
+Breast feeding women are not eligible
+For women of childbearing potential, no pregnancy or breast-feeding
+-  Pregnant or breast-feeding women
+Pregnant or breast-feeding
+Female patients who are pregnant or breast feeding
+Female patients who are pregnant or breast-feeding
+Women who are pregnant or breast-feeding
+Pregnant or breast-feeding patients
+Pregnancy or breast feeding
+Female who is pregnant or breast feeding and HCV treatment requires use of ribavirin
+Pregnant or breast-feeding women, due to the unknown effects of GI-6207 on the fetus or infant
+Breast feeding women
+Pregnancy or breast feeding
+Pregnant or breast-feeding females
+Pregnant or breast-feeding females
+Patients known or found to be pregnant or who is unwilling to stop breast-feeding
+Patients who are pregnant or breast-feeding
+Pregnancy or breast feeding
+Females who are pregnant or breast-feeding
+Women who are pregnant or breast feeding
+Women who are pregnant or breast feeding
+Women who are pregnant or breast-feeding
+Pregnant or breast feeding females
+Pregnant or breast-feeding females
+Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the study
+Currently breast feeding.
+Women who are pregnant or breast-feeding
+Pregnant or breast feeding female patient
+They are pregnant or breast feeding.
+Patients that are pregnant, breast feeding, or unwilling to use effective contraception during the study
+Female participant who is pregnant or breast-feeding
+Patients who are pregnant or breast-feeding
+Patients who are pregnant or breast feeding
+Is pregnant or breast-feeding
+Subject is pregnant or breast-feeding. Women must not breast-feed until at 5 months after completion of study participation..
+Currently pregnant or breast-feeding
+The patient is pregnant or breast feeding.
+Pregnant or breast-feeding females
+Female participants who are lactating, breast feeding, or pregnant.
+Female subject who is pregnant or breast-feeding, or any subject expecting to conceive or father a child during this study;
+Non pregnant, non-breast feeding females under active contraception
+Pregnant or breast-feeding
+Patients who are breast-feeding
+Pregnancy or breast feeding mother
+Pregnant or breast-feeding females or females who intend to become pregnant during study participation.
+Female patients who are pregnant or breast feeding are not eligible
+Women must not be pregnant or breast-feeding
+Pregnant or breast-feeding females
+Pregnant or breast-feeding women.
+Women who are pregnant or breast feeding.
+Pregnant or breast feeding women
+Pregnancy or breast feeding.
+Subject is pregnant or breast feeding
+Women who are pregnant or breast-feeding
+Pregnant or breast feeding
+Pregnant or breast-feeding females
+Women who are pregnant or breast feeding; women with a positive pregnancy test on enrollment or prior to study drug administration
+Pregnancy or breast feeding
+Pregnant or breast-feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
+Pregnant or breast-feeding women
+Female subjects who are pregnant or breast feeding
+Women who are either breast feeding or pregnant.
+Currently pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment
+Pregnancy or breast feeding
+Women who are pregnant or breast-feeding.
+Pregnant or breast-feeding
+Subject is pregnant or breast feeding
+Women who are pregnant (including positive pregnancy test at enrollment or prior to study drug administration) or breast-feeding
+Breast-feeding women
+Patients who are pregnant or breast-feeding.
+Pregnancy or breast feeding
+Pregnant or breast-feeding females
+Women who are pregnant or breast feeding are not to be included.
+Pregnancy or breast feeding
+Pregnant or breast feeding patients
+Females must not be pregnant or breast-feeding
+Pregnant or breast-feeding women
+Pregnant or lactating/breast-feeding women.
+Women of child-bearing potential who are pregnant or breast feeding
+Subjects are pregnant or breast-feeding at entry.
+Pregnant or breast-feeding females
+Pregnancy and breast feeding
+Female patients who are pregnant or breast-feeding, or intends to become pregnant during the study
+Females who are pregnant or breast feeding are not eligible for this study
+The patient is pregnant or breast feeding.
+Females who are breast-feeding or pregnant
+Women who are pregnant or breast feeding
+Not pregnant or breast-feeding
+Pregnant or breast-feeding women will not be entered on this study; women of child-bearing age must obtain a pregnancy test, and pregnant or breast feeding females are excluded
+Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding;
+Women who are pregnant or breast-feeding
+Pregnancy or breast-feeding
+Is pregnant or breast-feeding
+Pregnant or breast feeding at time of consent
+Patient is pregnant or breast-feeding.
+Pregnant or breast feeding females
+Participant is pregnant or breast feeding.
+Women must not be pregnant or breast-feeding
+Pregnant or breast-feeding females
+Pregnant or breast feeding
+Patient is pregnant or breast-feeding
+Patients who are pregnant or breast-feeding
+Female subject is pregnant or breast-feeding
+A female patient who is pregnant or breast-feeding
+Pregnant or breast feeding females
+Pregnant or breast-feeding females; patients who become pregnant during active therapy will be immediately removed from the study
+Women who are pregnant or breast-feeding
+Female participants pregnant or breast-feeding
+Pregnant or breast-feeding patients
+Pregnant or breast-feeding
+Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec
+The subject is pregnant or breast-feeding
+If female, patient is pregnant or breast-feeding.
+Pregnant or breast-feeding female patients;
+Patients who are pregnant or breast-feeding are not eligible for this study; negative pregnancy tests must be obtained in female patients who are postmenarchal
+Women who are pregnant or breast feeding
+Women who are breast feeding
+Females who are pregnant or breast-feeding
+Women who are pregnant or breast-feeding
+Breast feeding or pregnant
+Pregnant or breast-feeding female patients
+Female patients who are lactating must agree to stop breast-feeding
+Breast feeding or pregnant.
+Pregnant, lactating, or breast feeding women
+Pregnancy or breast-feeding women
+Women who are pregnant or breast-feeding
+Breast feeding or pregnant
+Women who are pregnant or breast-feeding
+Women who are pregnant or breast feeding
+Subjects who are pregnant or breast feeding.
+Patients who are currently pregnant, planning to become pregnant, or breast-feeding
+Pregnant or breast feeding females
+Pregnant or breast-feeding
+Pregnant or breast-feeding women.
+Women who are breast feeding or pregnant as evidenced by positive serum pregnancy test.
+Lactating women who are breast-feeding
+Female participants pregnant or breast-feeding
+Women who are pregnant or breast feeding
+Breast feeding women.
+Pregnant patients or currently breast-feeding
+Patient is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
+Pregnant or breast feeding females
+Patients who are pregnant or breast-feeding
+Pregnant or breast-feeding patients
+Patients who are pregnant or breast-feeding
+Pregnancy or breast-feeding
+Pregnant patients or women who are breast-feeding (patients must be postmenopausal)
+Patients who are pregnant or breast-feeding
+Women who are pregnant or breast-feeding
+Patients who are pregnant or breast feeding are NOT eligible for participation
+Pregnant or breast-feeding females
+Women who are pregnant or breast-feeding.
+Female patients who are pregnant or breast-feeding
+Pregnancy or breast feeding
+Women of child-bearing potential who are pregnant or breast feeding.
+Pregnant or breast-feeding women
+Female patients who are pregnant or breast-feeding
+Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking pomalidomide)
+Breast feeding females
+Pregnant or breast-feeding
+Females who are pregnant or breast feeding
+Pregnant or breast-feeding; pregnancy testing will be performed on all menstruating females within 14 days prior to study enrollment
+Pregnant women or women who are breast-feeding
+Female patients who are pregnant or breast feeding
+Female patient pregnant or breast feeding
+Pregnant or breast-feeding
+Breast feeding (Female only)
+DONOR: Breast feeding (Female only)
+Women of childbearing potential who are pregnant or breast feeding.
+Female patients who are pregnant or breast-feeding
+Female participants who were breast feeding or pregnant.
+Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
+For women only - currently pregnant or breast feeding.
+Patients who are breast-feeding
+Pregnant or breast-feeding women
+Patients who are pregnant or breast-feeding will NOT be eligible for participation
+Pregnancy or breast-feeding women
+Pregnant or breast feeding females.
+Pregnant (positive serum pregnancy test) or breast feeding
+Pregnancy or breast-feeding.
+Female subject is pregnant or breast-feeding
+Pregnant women or women who are breast-feeding
+Pregnant or breast-feeding; pregnancy testing will be performed on all menstruating females within 14 days prior to study enrollment
+Female patients who are pregnant or breast feeding
+Pregnant or breast feeding women
+Pregnant or breast feeding females.(Lactating females must agree not to breast feed while taking lenalidomide).
+Pregnant, inadequate contraception, breast feeding
+Lactating or breast feeding females
+Women who are pregnant or breast-feeding
+Pregnant or breast feeding
+Pregnant or breast feeding women
+Pregnant or breast feeding
+Pregnant or breast-feeding females
+Pregnant or breast feeding females are not eligible
+Females who are pregnant or breast-feeding
+Breast feeding must be discontinued
+Pregnant or breast-feeding females; (lactating females must agree not to breast feed while taking Revlimid)
+Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide or azacitidine)
+Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
+Female patients who are pregnant or breast-feeding
+Pregnant or breast feeding
+A woman who is pregnant or breast feeding
+Women who are pregnant or breast-feeding
+Pregnancy or breast feeding.
+Female patients who are pregnant or breast feeding
+Pregnancy or breast feeding
+Females who are pregnant or are breast-feeding.
+Breast feeding women;
+Pregnant women; breast feeding should be discontinued during treatment
+Patient is pregnant or breast feeding or expecting to conceive or father children within the projected duration of the study, because of the potential for serious adverse reactions in nursing infants from vorinostat, breast feeding must be discontinued for the duration of therapy with vorinostat
+Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
+Pregnant or breast feeding women
+For females, if they are pregnant or breast-feeding
+Pregnant or intending to become pregnant or breast-feeding patents
+Breast feeding
+Pregnant or breast-feeding women are excluded
+Pregnant (positive pregnancy test) or breast feeding
+Pregnant or breast-feeding women are ineligible
+Female subject is pregnant or breast-feeding.
+Pregnancy or breast-feeding
+Pregnant or breast-feeding female
+Women who are pregnant or breast feeding.
+Subject who is pregnant or breast feeding
+Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking ibrutinib or idelalisib)
+Pregnant women or women who are breast-feeding
+Women who are pregnant or breast-feeding.
+Pregnant or breast-feeding patients.
+Pregnant or breast feeding
+Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment.
+Patients who are pregnant or breast-feeding
+Pregnant or breast-feeding
+Is pregnant or breast-feeding
+Women who are breast-feeding or pregnant.
+Pregnant or breast feeding
+Pregnant or breast-feeding
+Women who are pregnant or breast-feeding.
+Women who are pregnant or breast-feeding
+Pregnant, lactating or breast feeding women
+Pregnancy or breast-feeding.
+Subjects who are pregnant or are breast-feeding
+Women currently pregnant or breast feeding.
+Pregnant or breast-feeding women are excluded.
+Females who are breast-feeding or pregnant
+Pregnant or breast-feeding women
+Women who are pregnant or breast-feeding
+Pregnant or breast-feeding
+Pregnancy or breast feeding
+Women who are pregnant or breast-feeding
+Female participants who are breast-feeding
+Pregnant (positive serum pregnancy test) or breast feeding
+Patients may not be pregnant or breast feeding
+Pregnant or breast feeding females
+are pregnant or breast-feeding.
+Are pregnant and or breast feeding.
+Pregnancy or breast-feeding
+Breast feeding or pregnant females
+Pregnancy or breast-feeding
+Women who are breast feeding or pregnant as evidenced by pregnancy test.
+Female patients who are pregnant or breast feeding
+Pregnancy or breast feeding
+If female, is pregnant or breast-feeding;
+Female participants who are pregnant, lactating, or breast-feeding
+Pregnant women and women who are breast-feeding
+Breast-feeding women
+Breast feeding or pregnant females
+Patients who are pregnant or breast-feeding.
+Pregnancy or breast-feeding.
+If female, is lactating or breast feeding
+Women who are pregnant or breast feeding.
+Pregnant or breast feeding
+Pregnant or breast-feeding women
+Subjects who are pregnant or breast feeding.
+Pregnant or breast feeding within the projected duration of trial participation through 4 months after the last dose of study treatment.
+Pregnant or breast feeding women
+Is pregnant or breast feeding
+Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
+Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.
+Breast feeding females
+Currently pregnant or breast-feeding.
+Women who are pregnant or breast feeding.
+Pregnant or breast-feeding females
+Pregnant or breast feeding
+Women who are pregnant or breast-feeding
+Women who are pregnant or breast feeding are not to be included.
+Pregnant women or women presently breast-feeding
+Pregnant or breast feeding
+Women who are pregnant or breast feeding
+Pregnant or breast-feeding females.
+Breast feeding
+Pregnancy/Breast feeding
+Not breast feeding
+DONOR: Not breast feeding
+Subjects in their reproductive age who are breast feeding or have a positive pregnancy test
+Patient is breast feeding
+Not breast feeding
+Pregnant or breast-feeding women will not be entered on this study
+Pregnancy or breast-feeding.
+Pregnant or breast-feeding
+Women who are pregnant or breast-feeding.
+Is pregnant or breast-feeding
+Pregnancy or breast-feeding.
+Women of childbearing potential who are pregnant or breast feeding.
+Pregnant or breast feeding
+Pregnant or breast feeding
+Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
+Pregnant, lactating or actively breast feeding females.
+Breast feeding women
+Pregnant or breast feeding females (lactating females must agree not to breast feed while taking ipilimumab)
+Pregnancy or breast-feeding
+Pregnant or breast feeding females; lactating females must agree not to breast feed while taking lenalidomide
+Pregnant or breast feeding
+Pregnant and/or breast-feeding women.
+Pregnant or breast feeding
+Pregnant or breast-feeding women
+Females in the study must not be pregnant or breast feeding and not planning to become pregnant or breast feed for the duration of the study, and for at least three months after study completion
+Pregnancy or breast-feeding.
+Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events.
+The patient is pregnant or breast feeding.
+Breast feeding females
+Subjects who are pregnant or are breast-feeding.
+Women who are pregnant or breast-feeding
+Women who are pregnant or breast-feeding
+Lactating females who are actively breast feeding.
+Not breast feeding
+DONOR: Not breast feeding
+Pregnant or breast-feeding females
+Patients who are pregnant or breast-feeding
+Pregnant or breast-feeding women.
+Pregnant or breast-feeding women
+Pregnant or breast feeding.
+Pregnant or breast feeding
+Pregnancy or breast-feeding
+Women of child-bearing potential who are pregnant or breast feeding
+Pregnancy or breast feeding
+Pregnant or breast-feeding
+Not pregnant or breast-feeding
+Pregnancy or breast feeding.
+Women who are currently pregnant or breast-feeding
+Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
+Female patients who are lactating must agree to stop breast-feeding
+pregnant or breast feeding
+Pregnancy or breast feeding
+Patients must not be pregnant or breast feeding and must practice adequate contraception
+Patient is pregnant or nursing/breast-feeding.
+Pregnant or breast feeding
+Pregnant or breast-feeding.
+Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
+Pregnant or breast-feeding, or planning to become pregnant during study treatment and within 2 months after the last administration of investigational product.
+Women who are pregnant or breast feeding.
+If you are pregnant or breast feeding
+Pregnant or breast-feeding females
+Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the study
+Patient is pregnant or breast-feeding
+Women who are pregnant or breast feeding
+Women who are pregnant, become pregnant, or are breast-feeding
+Women who are currently breast-feeding are not eligible for this study
+Currently pregnant or breast-feeding
+Female patients who are pregnant or breast-feeding
+Breast feeding women.
+Pregnant or breast feeding
+Must not be pregnant or breast feeding
+Females who are pregnant or might be pregnant or are breast-feeding
+Women who are pregnant or breast feeding will not be included in the study
+May not be pregnant, lactating or breast feeding
+Current pregnancy and breast feeding
+Not pregnant or breast?feeding
+Pregnancy or breast feeding
+Pregnant or breast feeding
+Pregnancy or breast feeding
+Pregnant or breast-feeding
+Pregnant and/or breast feeding if a female recipient
+Pregnant or breast feeding
+Patients who are pregnant or breast feeding
+Females who are pregnant or breast feeding
+Pregnant and breast-feeding women are ineligible
+Females who are pregnant, breast-feeding or intending to become pregnant; this exclusion criterion will be assessed by questioning the patient about the pregnancy status, breast-feeding status, the intent to become pregnant, the menopausal status, and the date of the last menstrual period
+Women who are pregnant or breast feeding
+Lactation or breast feeding.
+Pregnant or breast feeding
+Pregnant women or women who are breast feeding are not eligible for the study
+Pregnant or breast-feeding.
+Females who are pregnant or breast feeding at the time of screening will not be eligible for this study
+Subject is not pregnant or breast feeding, and cannot become pregnant within 30 days after the end of treatment
+Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after end of treatment
+Pregnant or breast feeding females
+Pregnant or breast feeding females
+Pregnant patients or actively breast-feeding
+Women who are currently pregnant or breast feeding
+Pregnant or breast feeding
+Subject is pregnant (documented by a positive pregnancy test according to hospital standard practices) or is actively breast-feeding.
+(Female only) Breast feeding
+Pregnant or breast-feeding women
+Pregnancy or breast feeding
+At the beginning of the study, pregnant women and women who are breast-feeding will not be enrolled
+CONTROL (HEALTHY) GROUP: At the beginning of the study, pregnant women and women who are breast-feeding will not be enrolled
+Breast feeding
+Women must be one year from pregnancy and breast-feeding
+Women currently pregnant or breast-feeding at time of study consent
+Participants who have a positive pregnancy test, are pregnant, or breast feeding
+Pregnant or breast feeding
+Pregnant and/or breast-feeding
+Pregnancy or breast feeding
+Patient is pregnant or breast-feeding
+Pregnancy/breast feeding: females who are pregnant or breast feeding at the time of study entry are not eligible
+Women who are pregnant or breast-feeding
+Patients who are pregnant, planning pregnancy, or breast feeding
+Not be currently pregnant or breast feeding
+Pregnant or breast-feeding
+Women who are pregnant or breast-feeding
+Breast feeding women
+Pregnant, planning to become pregnant starting from 28 days prior to receiving CC-486 throughout your participation in the study, and for at least 90 days following your last dose of study treatment, or breast-feeding females
+Pregnancy or breast-feeding.
+Pregnant or breast feeding
+Women who are currently pregnant or breast-feeding
+Pregnant or breast feeding
+Breast feeding
+Is pregnant or breast feeding
+Female patients who are pregnant or breast feeding
+Female subjects must not be pregnant or breast feeding within 6 months prior to and during course of study
+Women must not be pregnant or breast-feeding
+Pregnant women or those who are breast feeding
+Children, minors, pregnant women, women who are breast feeding, institutionalized patients
+Known pregnancy or breast-feeding
+Patient must NOT be pregnant or breast-feeding
+Women that are pregnant or breast-feeding
+Not pregnant or breast feeding
+Pregnant, lactating, or breast feeding women
+Women who are pregnant or breast-feeding
+Patients who are currently pregnant or breast feeding; a pregnancy test within 72 hours of the first PET/MRI will be performed
+Women who are pregnant or breast-feeding
+Breast feeding / pregnancy
+Pregnant or currently breast-feeding
+Breast-feeding
+Pregnant women or women who are breast-feeding
+Pregnant women or women who are breast feeding
+Known pregnancy or breast-feeding
+Women who are pregnant of breast-feeding
+Women who are pregnant or breast feeding
+Breast feeding/pregnancy
+Breast-feeding
+Pregnancy or lactating with the intent of breast feeding
+Subjects who are pregnant or breast feeding
+No breast-feeding
+Known pregnancy or breast-feeding
+Not pregnant or breast-feeding
+Not pregnant or breast feeding
+Patient Volunteers/Contrast Enhancement Sub-group: Not pregnant or breast-feeding
+Breast feeding
+Pregnant or breast-feeding
+Pregnancy or breast feeding
+Female patients cannot be pregnant or breast feeding
+OVARIAN CANCER PARTICIPANTS: Patient is pregnant or breast-feeding
+BREAST CANCER PARTICIPANTS: Patient is pregnant or breast-feeding
+Women who are pregnant or breast-feeding
+Not breast-feeding, if applicable
+Women who are either pregnant or breast feeding
+Pregnant or breast-feeding women
+Pregnancy or breast-feeding
+Pregnant or breast feeding.
+Pregnant or breast-feeding females
+Female pregnant or breast feeding
+Patients who are pregnant or are breast feeding
+Patients who are pregnant, breast-feeding or are planning to become pregnant during the study duration
+Is breast-feeding or pregnant
+pregnancy or breast-feeding
+Subjects who are pregnant or breast feeding
+Women must not be pregnant or breast-feeding
+Pregnant or breast feeding female patient
+Pregnant or breast feeding women
+The patient is pregnant or breast feeding
+Women who are pregnant or breast feeding
+Pregnant or breast-feeding
+Pregnant women or women who are breast feeding
+Participant is pregnant or breast-feeding
+Patients who are breast feeding
+Pregnancy and contraception: Subjects who are pregnant, breast-feeding or planning to conceive within 30 days are not eligible
+Pregnant or breast feeding women
+Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit
+Pregnant or breast feeding
+Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec.
+Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit
+Patient is pregnant or breast-feeding.
+Pregnant or breast-feeding women will not be entered on this study; women of child-bearing age must obtain a pregnancy test and pregnant or breast feeding females are excluded